• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $MBIO

    Mustang Bio Inc.

    Subscribe to $MBIO
    $MBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

    IPO Year:

    Exchange: NASDAQ

    Website: mustangbio.com

    Peers

    $ATXI
    $FBIO
    $GOSS

    Recent Analyst Ratings for Mustang Bio Inc.

    DatePrice TargetRatingAnalyst
    1/24/2022$13.00 → $6.00Buy
    B. Riley Securities
    See more ratings

    Mustang Bio Inc. SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mustang Bio Inc.

      SCHEDULE 13G/A - MUSTANG BIO, INC. (0001680048) (Subject)

      5/9/25 4:03:11 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Mustang Bio Inc.

      EFFECT - MUSTANG BIO, INC. (0001680048) (Filer)

      4/14/25 12:15:13 AM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POS AM filed by Mustang Bio Inc.

      POS AM - MUSTANG BIO, INC. (0001680048) (Filer)

      4/4/25 4:30:31 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Mustang Bio Inc.

      SCHEDULE 13D/A - MUSTANG BIO, INC. (0001680048) (Subject)

      4/2/25 5:16:30 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POS EX filed by Mustang Bio Inc.

      POS EX - MUSTANG BIO, INC. (0001680048) (Filer)

      4/1/25 5:26:32 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Mustang Bio Inc.

      424B3 - MUSTANG BIO, INC. (0001680048) (Filer)

      4/1/25 5:25:53 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Mustang Bio Inc.

      10-K - MUSTANG BIO, INC. (0001680048) (Filer)

      3/28/25 8:02:57 AM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mustang Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - MUSTANG BIO, INC. (0001680048) (Filer)

      3/5/25 4:30:48 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14C filed by Mustang Bio Inc.

      DEF 14C - MUSTANG BIO, INC. (0001680048) (Filer)

      3/3/25 5:51:47 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Mustang Bio Inc.

      424B3 - MUSTANG BIO, INC. (0001680048) (Filer)

      2/27/25 5:04:52 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Mustang Bio Inc. Financials

    Live finance-specific insights

    See more

    Mustang Bio Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

      Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials evaluating DFD-29 demonstrated achievement of co-primary and all secondary endpoints versus placebo and Oracea® (doxycycline) with no significant safety issues Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in the second half of 2023 for DFD-29 and CUTX-101 Cosibelimab longer-term results demonstrated substantial increases in complete response rates in advanced cutaneous squamous cell carcinoma PDUFA goal date of January 3, 2024, set by FDA for cosi

      8/14/23 4:01:50 PM ET
      $ATXI
      $CKPT
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

      95% overall response rate, 65% complete response rate and favorable safety profile in patients treated with modified cell manufacturing process Data presented at the 63rd American Society of Hematology (ASH) Annual Meeting Key opinion leader conference call on Thursday, December 16, 2021, at 2:30 p.m. EST WORCESTER, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced updated data from the ongoing Phase 1/2 clinical trial of MB-106,

      12/13/21 9:00:00 AM ET
      $FBIO
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

      WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement as required by Nasdaq Listing Rule 5550(b)(1). On February 26, 2025, Mustang received formal notice from Nasdaq confirming that the Company has satisfied the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1). As previously disclosed, the Company regained compliance with the minimum bid price requirement under Nasdaq Listing Rule

      3/5/25 4:15:15 PM ET
      $FBIO
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

      WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the exit of the lease for its manufacturing facility in Worcester, Massachusetts and concurrent divestment of certain fixed assets including furniture and equipment to AbbVie Bioresearch Center Inc., a Delaware corporation ("AbbVie"), for $1.0 million. Mustang has relocated its corporate headquarters to 95 Sawyer Road, Waltham, Massachusetts. Mustang expects to continue to rely on its academic part

      2/27/25 4:05:27 PM ET
      $FBIO
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

      WORCESTER, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing. In addition, as a result of the closing of the public offering announced by the Company on February 10, 2025, the Company believes that it has a minimum of $2.5 million in stockholders' equity for continued listing on the Nasdaq Capital Market as required by Nasdaq Listing Rule 5550(b)(1). The Company is awaiting a formal compliance determin

      2/11/25 4:10:30 PM ET
      $FBIO
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mustang Bio Announces Closing of $8 Million Public Offering

      WORCESTER, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the closing of its previously announced public offering, for the issuance and sale of an aggregate of 2,657,807 shares of its common stock (or common stock equivalents in lieu thereof), Series C-1 warrants to purchase up to 2,657,807 shares of common stock and Series C-2 warrants to purchase up to 2,657,807 shares of common stock, at a combined public offering price of $3.01 per share (or per commo

      2/10/25 8:00:23 AM ET
      $FBIO
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mustang Bio Announces Pricing of $8 Million Public Offering

      WORCESTER, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the pricing of a public offering of an aggregate of 2,657,807 shares of its common stock (or common stock equivalents in lieu thereof), Series C-1 warrants to purchase up to 2,657,807 shares of common stock and Series C-2 warrants to purchase up to 2,657,807 shares of common stock, at a combined public offering price of $3.01 per share (or per common stock equivalent in lieu thereof) and accompanyi

      2/6/25 7:00:39 AM ET
      $FBIO
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mustang Bio Announces Reverse Stock Split

      WORCESTER, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced that it will effect a 1-for-50 reverse stock split of its issued and outstanding common stock. Mustang expects its common stock to begin trading on a split-adjusted basis on The Nasdaq Stock Market as of the commencement of trading on January 16, 2025. The reverse stock split was approved on June 27, 2024 by Mustang's Board of Directors and stockholders representing approximately 56% of the voting

      1/14/25 8:00:15 AM ET
      $FBIO
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mustang Bio Receives Positive Listing Determination from Nasdaq

      WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced that by decision dated November 8, 2024, the Nasdaq Hearings Panel granted the Company's request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $1.00 bid price requirement through January 31, 2025 and the $2.5 million stockholders' equity requirement through February 18, 2025. The Company is considering all avai

      11/12/24 8:30:24 AM ET
      $FBIO
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

      MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial Preclinical data support a novel combination of MB-108 (HSV-1 oncolytic virus) and MB-101 (IL13Rα2‐targeted CAR-T cell therapy) to optimize clinical results WORCESTER, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation to Mustang for MB-10

      11/7/24 8:30:59 AM ET
      $FBIO
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

      WORCESTER, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 16,877,638 shares of its common stock having an exercise price of $0.237 per share, originally issued in May 2024. The issuance or resale of the shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement

      10/24/24 2:10:15 PM ET
      $FBIO
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

      WORCESTER, Mass., June 21, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules, for the issuance and sale of an aggregate of 6,130,000 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.41 per share (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a

      6/21/24 4:01:58 PM ET
      $FBIO
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Mustang Bio Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities reiterated coverage on Mustang Bio with a new price target

      B. Riley Securities reiterated coverage of Mustang Bio with a rating of Buy and set a new price target of $6.00 from $13.00 previously

      1/24/22 8:55:18 AM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Mustang Bio with a new price target

      BTIG Research initiated coverage of Mustang Bio with a rating of Buy and set a new price target of $11.00

      5/18/21 6:47:29 AM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Mustang Bio Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, CEO and Interim CFO Litchman Manuel Md covered exercise/tax liability with 27 shares, decreasing direct ownership by 2% to 1,634 units (SEC Form 4)

      4 - MUSTANG BIO, INC. (0001680048) (Issuer)

      4/28/25 4:30:13 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Fortress Biotech, Inc. was granted 67,806 shares, increasing direct ownership by 52% to 198,858 units (SEC Form 4)

      4 - MUSTANG BIO, INC. (0001680048) (Issuer)

      4/2/25 4:05:14 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Fortress Biotech, Inc. claimed ownership of 6,552,784 shares (SEC Form 3)

      3 - MUSTANG BIO, INC. (0001680048) (Issuer)

      1/3/25 4:20:31 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Jin David claimed ownership of 1,994 shares (SEC Form 3)

      3 - MUSTANG BIO, INC. (0001680048) (Issuer)

      10/29/24 4:05:16 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Fortress Biotech, Inc. was granted 575,191 shares, increasing direct ownership by 30% to 2,502,991 units (SEC Form 4)

      4 - MUSTANG BIO, INC. (0001680048) (Issuer)

      6/28/24 4:22:34 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Litchman Manuel Md covered exercise/tax liability with 1,396 shares, decreasing direct ownership by 2% to 83,024 units (SEC Form 4)

      4 - MUSTANG BIO, INC. (0001680048) (Issuer)

      6/4/24 8:35:40 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Litchman Manuel Md covered exercise/tax liability with 2,820 shares, decreasing direct ownership by 3% to 79,420 units (SEC Form 4)

      4 - MUSTANG BIO, INC. (0001680048) (Issuer)

      6/4/24 8:33:33 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Murphy James B

      3 - MUSTANG BIO, INC. (0001680048) (Issuer)

      2/12/24 4:13:59 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fortress Biotech, Inc. was granted 419,092 shares, increasing direct ownership by 28% to 1,927,800 units (SEC Form 4)

      4 - MUSTANG BIO, INC. (0001680048) (Issuer)

      1/3/24 4:29:43 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Carney Peter claimed ownership of 3,992 shares (SEC Form 3)

      3 - MUSTANG BIO, INC. (0001680048) (Issuer)

      12/19/23 4:06:38 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Mustang Bio Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mustang Bio Inc.

      SC 13G/A - MUSTANG BIO, INC. (0001680048) (Subject)

      11/14/24 4:21:44 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Mustang Bio Inc.

      SC 13D/A - MUSTANG BIO, INC. (0001680048) (Subject)

      6/28/24 4:26:23 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Mustang Bio Inc.

      SC 13G - MUSTANG BIO, INC. (0001680048) (Subject)

      2/14/24 3:42:37 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Mustang Bio Inc. (Amendment)

      SC 13D/A - MUSTANG BIO, INC. (0001680048) (Subject)

      1/13/23 4:13:56 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Mustang Bio Inc.

      SC 13G - MUSTANG BIO, INC. (0001680048) (Subject)

      7/8/22 4:57:02 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Mustang Bio, Inc. (Amendment)

      SC 13G/A - MUSTANG BIO, INC. (0001680048) (Subject)

      4/9/21 6:02:54 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed

      SC 13G - MUSTANG BIO, INC. (0001680048) (Subject)

      2/2/21 3:08:33 PM ET
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care